Observational studyBMJ open diabetes research & care2021

Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry).

Kohjiro Ueki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.